IMCR FY 2024 Earnings — Immunocore Holdings plc Revenue & Financial Results | Market Cap Arena

IMCRImmunocore Holdings plc

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$248M-0.7% YoY

Gross Profit

$239M96.6% margin

Operating Income

-$56M-22.7% margin

Net Income

-$41M-16.5% margin

EPS (Diluted)

$-1.02

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$21M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$649M

Stockholders' Equity

$361M

Cash & Equivalents

$456M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$248M	$249M	-0.7%
Gross Profit	$239M	$248M	-3.6%
Operating Income	-$56M	-$60M	+5.6%
Net Income	-$41M	-$55M	+26.2%